@article{WhiteheadOehlschlaegerAlmajhdietal.2014,
  author    = {Whitehead, Mark and {\"O}hlschl{\"a}ger, Peter and Almajhdi, Fahad N. and Alloza, Leonor and Marz{\´a}bal, Pablo and Meyers, Ann E. and Hitzeroth, Inga I. and Rybicki, Edward P.},
  title     = {Human papillomavirus (HPV) type 16 E7 protein bodies cause tumour regression in mice},
  series = {BMC cancer},
  journal   = {BMC cancer},
  number    = {14:367},
  publisher = {BioMed Central},
  address   = {London},
  issn      = {1471-2407},
  doi       = {10.1186/1471-2407-14-367},
  pages     = {1 -- 15},
  year      = {2014},
  language  = {en}
}
@article{OehlschlaegerQuettingAlvarezetal.2009,
  author    = {{\"O}hlschl{\"a}ger, Peter and Quetting, Michael and Alvarez, Gerardo and D{\"u}rst, Matthias and Gissmann, Lutz and Kaufmann, Andreas M.},
  title     = {Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants},
  series = {International Journal of Cancer},
  volume    = {125},
  journal   = {International Journal of Cancer},
  number    = {1},
  publisher = {Wiley},
  address   = {Weinheim},
  isbn      = {1097-0215},
  pages     = {189 -- 198},
  year      = {2009},
  language  = {en}
}
@article{ManeaLeursOrbanetal.2011,
  author    = {Manea, Marilena and Leurs, Ulrike and Orban, Erika and Baranyai, Zsuzsa and {\"O}hlschl{\"a}ger, Peter and Marquardt, Andreas and Schulcz, Akos and Tejeda, Miguel},
  title     = {Enhanced Enzymatic Stability and Antitumor Activity of Daunorubicin-GnRH-III Bioconjugates Modified in Position 4},
  series = {Bioconjugate Chemistry},
  volume    = {22},
  journal   = {Bioconjugate Chemistry},
  number    = {7},
  publisher = {ACS},
  address   = {Washington, DC},
  isbn      = {1520-4812},
  pages     = {1320 -- 1329},
  year      = {2011},
  language  = {en}
}
@inproceedings{TakenagaHerreraWerneretal.2013,
  author    = {Takenaga, Shoko and Herrera, Cony F. and Werner, Frederik and Biselli, Manfred and Schnitzler, Thomas and Sch{\"o}ning, Michael Josef and {\"O}hlschl{\"a}ger, Peter and Wagner, Torsten},
  title     = {Detection of the metabolic activity of cells by differential measurements based on a single light-addressable potentiometric sensor chip},
  series = {11. Dresdner Sensor-Symposium : 9.-11.12.2013},
  booktitle = {11. Dresdner Sensor-Symposium : 9.-11.12.2013},
  organization    = {Dresdner Sensor-Symposium <11, 2013>},
  isbn      = {978-3-9813484-5-3},
  pages     = {63 -- 67},
  year      = {2013},
  language  = {en}
}
@article{LeursMezoOehlschlaegeretal.2012,
  author    = {Leurs, Ulrike and Mezo, Gabor and {\"O}hlschl{\"a}ger, Peter and Orban, Erika and Marquard, Andrea and Manea, Marilena},
  title     = {Design, synthesis, in vitro stability and cytostatic effect of multifunctional anticancer drug-bioconjugates containing GnRH-III as a targeting moiety},
  series = {Peptide Science},
  volume    = {98},
  journal   = {Peptide Science},
  number    = {1},
  publisher = {Wiley},
  address   = {New York, NY},
  issn      = {1097-0282},
  doi       = {10.1002/bip.21640},
  pages     = {1 -- 10},
  year      = {2012},
  abstract  = {Bioconjugates containing the GnRH-III hormone decapeptide as a targeting moiety are able to deliver chemotherapeutic agents specifically to cancer cells expressing GnRH receptors, thereby increasing their local efficacy while limiting the peripheral toxicity. However, the number of GnRH receptors on cancer cells is limited and they desensitize under continuous hormone treatment. A possible approach to increase the receptor mediated tumor targeting and consequently the cytostatic effect of the bioconjugates would be the attachment of more than one chemotherapeutic agent to one GnRH-III molecule. Here we report on the design, synthesis and biochemical characterization of multifunctional bioconjugates containing GnRH-III as a targeting moiety and daunorubicin as a chemotherapeutic agent. Two different drug design approaches were pursued. The first one was based on the bifunctional [4Lys]-GnRH-III (Glp-His-Trp-Lys-His-Asp-Trp-Lys-Pro-Gly-NH2) containing two lysine residues in positions 4 and 8, whose ϵ-amino groups were used for the coupling of daunorubicin. In the second drug design, the native GnRH-III (Glp-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH2) was used as a scaffold; an additional lysine residue was coupled to the ϵ-amino group of 8Lys in order to generate two free amino groups available for conjugation of daunorubicin. The in vitro stability/degradation of all synthesized compounds was investigated in human serum, as well as in the presence of rat liver lysosomal homogenate. Their cellular uptake was determined on human breast cancer cells and the cytostatic effect was evaluated on human breast, colon and prostate cancer cell lines. Compared with a monofunctional compound, both drug design approaches resulted in multifunctional bioconjugates with increased cytostatic effect.},
  language  = {en}
}
@article{AlmajhdiSengerAmeretal.2014,
  author    = {Almajhdi, Fahad N. and Senger, Tilo and Amer, Haitham M. and Gissmann, Lutz and {\"O}hlschl{\"a}ger, Peter},
  title     = {Design of a highly effective therapeutic HPV16 E6/E7-specific DNA vaccine: optimization by different ways of sequence rearrangements (Shuffling)},
  series = {PLOS one},
  volume    = {11},
  journal   = {PLOS one},
  number    = {9},
  publisher = {PLOS},
  address   = {San Francisco},
  issn      = {1932-6203},
  doi       = {10.1371/journal.pone.0113461},
  pages     = {e113461},
  year      = {2014},
  abstract  = {Persistent infection with the high-risk Human Papillomavirus type 16 (HPV 16) is the causative event for the development of cervical cancer and other malignant tumors of the anogenital tract and of the head and neck. Despite many attempts to develop therapeutic vaccines no candidate has entered late clinical trials. An interesting approach is a DNA based vaccine encompassing the nucleotide sequence of the E6 and E7 viral oncoproteins. Because both proteins are consistently expressed in HPV infected cells they represent excellent targets for immune therapy. Here we report the development of 8 DNA vaccine candidates consisting of differently rearranged HPV-16 E6 and E7 sequences within one molecule providing all naturally occurring epitopes but supposedly lacking transforming activity. The HPV sequences were fused to the J-domain and the SV40 enhancer in order to increase immune responses. We demonstrate that one out of the 8 vaccine candidates induces very strong cellular E6- and E7- specific cellular immune responses in mice and, as shown in regression experiments, efficiently controls growth of HPV 16 positive syngeneic tumors. This data demonstrates the potential of this vaccine candidate to control persistent HPV 16 infection that may lead to malignant disease. It also suggests that different sequence rearrangements influence the immunogenecity by an as yet unknown mechanism.},
  language  = {en}
}
@article{OehlschlaegerPesOsenetal.2006,
  author    = {{\"O}hlschl{\"a}ger, Peter and Pes, Michaela and Osen, Wolfram and D{\"u}rst, Matthias},
  title     = {An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response / {\"O}hlschl{\"a}ger, Peter ; Pes, Michaela ; Osen, Wolfram ; D{\"u}rst, Matthias ; Schneider, Achim ; Gissmann, Lutz ; Kaufman},
  series = {Vaccine. 24 (2006), H. 15},
  journal   = {Vaccine. 24 (2006), H. 15},
  isbn      = {0264-410X},
  pages     = {2880 -- 2893},
  year      = {2006},
  language  = {en}
}
@article{SpiessWilfriedAlvarezetal.2011,
  author    = {Spiess, Elmar and Wilfried, Reichardt and Alvarez, Gerardo and Gottrup, Marcus and {\"O}hlschl{\"a}ger, Peter},
  title     = {An Artificial PAP Gene Breaks Self-tolerance and Promotes Tumor Regression in the TRAMP Model for Prostate Carcinoma},
  series = {Molecular Therapy},
  volume    = {20},
  journal   = {Molecular Therapy},
  number    = {3},
  publisher = {Elsevier},
  address   = {Amsterdam},
  isbn      = {1525-0016},
  pages     = {555 -- 564},
  year      = {2011},
  language  = {en}
}
@article{OehlschlaegerOsenPeileretal.2001,
  author    = {{\"O}hlschl{\"a}ger, Peter and Osen, Wolfram and Peiler, Tanja and Caldeira, Sandra},
  title     = {A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity / Osen, Wolfram ; Peiler, Tanja ; {\"O}hlschl{\"a}ger, Peter ; Caldeira, Sandra ; Faath, Stefan ; Mich},
  series = {Vaccine. 19 (2001), H. 20},
  journal   = {Vaccine. 19 (2001), H. 20},
  isbn      = {0264-410X},
  pages     = {4276 -- 4286},
  year      = {2001},
  language  = {en}
}